Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma
Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma
Active, not recruiting · NCT05464433 · Registry updated 2025-03-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma | Extranodal Natural Killer T Cell Lymphoma | Active, not recruiting | Phase 1 / Phase 2 | 2025-03-13 | NCT05464433 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Sun Yat-sen University | 606 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Tongren Hospital, Capital Medical University | Beijing | China | 15 |
| Jiangxi Cancer Hospital | Nanchang | China | 18 |
| Peking Union Medical College Hospital | Beijing | China | 112 |
| Sun Yat-Sen University Cancer Center | Guangzhou | China | 66 |
| The First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University | Guangzhou | China | 1 |
| The Second Hospital of Dalian Medical University | Dalian | China | 8 |